SEMAGLUTIDE
- A GLP-1 receptor agonist (single pathway)
- Developed by Novo Nordisk
- Works by:
- reducing appetite
- slowing gastric emptying
- improving insulin response
Cycle length
- Same principle again:
- Semaglutide is NOT meant to be cycled
How it’s actually used:
- Designed for continuous, long-term use
- Clinical trials:
- Typically 68 weeks+
- Effects build gradually over months
Semaglutide 10 (10 mg/3ml/300units) 30 units = 1mg
- Weeks 1–4: 7 units weekly
- Weeks 5–8: 15 units weekly
Semaglutide 20 (20mg/3ml/300units) 15 units =1mg
- Weeks 9–12: 30 units weekly (This does is not for first time use)
- Weeks 13–16: 45 units weekly
- Weeks 17 Onwards: 60-75 units weekly (Repeat cycle until research is complete)
CAGRILINTIDE
- is an amylin analogue developed by Novo Nordisk.
- Mimics the hormone amylin (co-secreted with insulin)
- Works differently from GLP-1 drugs:
- increases satiety (you feel full faster)
- slows gastric emptying
- reduces food intake
- It’s often studied in combination with semaglutide (called “CagriSema”), which targets multiple appetite pathways.
Cycle length (research / real-world use)
- Same key principle as the others:
- Cagrilintide is NOT a cycle-based compound
In studies:
- Used as continuous therapy
- Trials typically run:
- 20–68 weeks+
- Effects build gradually over time
Cagrilintide 10 (10 mg/3ml/300units) 30 units = 1mg
- Weeks 1–4: 30 units weekly
- Weeks 5–8: 45 units weekly (Repeat cycle until research is complete)
Tissue Repair & Longevity
- GHK-Cu (short for glycyl-L-histidyl-L-lysine copper) is a naturally occurring copper-binding peptide found in human plasma, saliva, and urine. It’s very different from the weight-loss drugs you’ve been asking about.
What GHK-Cu is
- A tripeptide + copper ion
- Known for roles in:
- skin regeneration
- wound healing
- collagen production
- Widely used in cosmetics and dermatology research
What it’s studied for
- Research suggests GHK-Cu may:
- Stimulate collagen and elastin
- Improve skin elasticity and wrinkles
- Promote hair growth (early-stage evidence)
- Support wound healing and tissue repair
- Have anti-inflammatory and antioxidant effects
- Possible Cycle:
- 12 weeks followed by 1-2 months off, or month on month off
GHK-Cu 50 (50 mg/3ml/300units) 6 units = 1mg:
- 6–12 units nightly
GHK-CU 100 (100mg/3ml/300units) 3 units = 1mg:
- 3-6 units nightly
AHK-CU (COPPER PEPTIDE)
- A synthetic tripeptide complexed with copper composed of:
- Alanine
- Histidine
- Lysine
- Structurally similar in concept to GHK-Cu, but with a different amino acid sequence
- Studied for its role in cell signalling and tissue regeneration pathways
- Research interest focuses on its interaction with:
- dermal and connective tissue repair mechanisms
- extracellular matrix remodelling
- angiogenesis (new blood vessel formation) signalling
- inflammatory modulation pathways
What it’s studied for
- Research commonly investigates:
- skin regeneration and repair models
- collagen and elastin production pathways
- hair follicle stimulation mechanisms
- wound healing and tissue remodeling
- anti-inflammatory signalling effects
- cosmetic and dermatological regenerative research
Cycle length (research / anecdotal use)
- Common informal / experimental research patterns
- 4–12 weeks frequently discussed
- sometimes used longer in regenerative or cosmetic research models
- Typically explored as:
- daily or near-daily administration in study designs
- or periodic dosing depending on experimental goals
AHK-Cu — 20 mg / 3 ml / 300 units
- 5 units = 0.33 mg (330 mcg)
- 10 units = 0.67 mg
- 15 units = 1 mg
- 30 units = 2 mg
Theoretical research schedule examples
- Low protocol:
- = 5 units daily (≈0.33 mg)
- Moderate protocol:
- = 10 units daily (≈0.67 mg)
- Higher research example:
- = 15 units daily (≈1 mg)
20 mg total content example longevity
- 5 units/day → ~60 days
- 10 units/day → ~30 days
- 15 units/day → ~20 days
Common research pairing
- Often discussed alongside:
- GHK-Cu
- skin regeneration peptide protocols
- hair follicle stimulation research compounds
- extracellular matrix and collagen-support models
- Due to overlapping copper-peptide signalling pathways involved in tissue repair and remodeling.
TB-500
- A synthetic peptide fragment designed to mimic Tβ4 activity
- Involved in:
- cell migration
- angiogenesis (new blood vessel formation)
- tissue repair signaling
What it’s studied for
- Research areas include:
- muscle and tendon healing
- ligament recovery
- wound healing
- inflammation reduction
- possible cardiac repair effects
Cycle length” (research / anecdotal use)
- 1. “Loading phase”
- ~2–6 weeks
- Higher frequency dosing
- 2. “Maintenance phase”
- Additional weeks or intermittent use
- Typical total duration discussed:
- 4–12 weeks
TB500 20 (20 mg/3ml/300units) 15 units = 1mg:
- 5 units nightly or 15 units 2–3x weekly
BPC-157
- A synthetic fragment derived from a protein found in human gastric juice
- Not an approved medication
- Studied mainly in animal models
- It’s often categorized as a gut-derived healing peptide
What it’s studied for
- Research suggests potential effects on:
- tendon and ligament healing
- muscle repair
- gut lining protection (ulcers, inflammation)
- nerve healing
- angiogenesis (blood vessel formation)
One unique angle
- Strong focus on gut repair + systemic healing signaling
Cycle length” (research / anecdotal use)
- Like TB-500:
Common informal/research-style use patterns:
- Duration often discussed:
- 2–6 weeks (short protocols)
- sometimes extended to 8–12 weeks
- Used either:
- continuously during that period
- or until an injury “resolves”
BPC-157 20 (20 mg/3ml/300units) 15 units = 1mg:
- 5 units nightly
KPV
- A synthetic tripeptide fragment derived from α-MSH (alpha-melanocyte stimulating hormone)
- Not an approved medication
- Studied mainly in pre-clinical / animal models and experimental settings
- It is often categorized as an anti-inflammatory / gut-associated regulatory peptide
What it’s studied for
- Research suggests potential effects on:
- gut inflammation modulation
- intestinal barrier support
- inflammatory signalling pathways
- skin inflammation models
- mucosal healing pathways
- immune regulation mechanisms
One unique angle
- Strong focus on local anti-inflammatory signalling + gastrointestinal support
Cycle length (research / anecdotal use)
- Common informal / research-style use patterns
- Duration often discussed:
- 2–4 weeks (short protocols)
- sometimes extended to 6–8 weeks
- Used either:
- continuously during that period
- or until research objective / endpoint is reached
KPV-10 (10 mg / 3 ml / 300 units). 30 units = 1 mg, take 10 units nightly for 30 days and repeat for another 30 days. Have 1 month break and cycle once again.
WOLVERINE BLEND
- A dual peptide formulation:
- BPC-157 → gut-derived, tendon/ligament + localized repair
- TB-500 → systemic repair, cell migration, angiogenesis
- The nickname comes from the Wolverine character because of his rapid healing ability.
Why they’re combined
- The idea is “synergy”:
- BPC-157:
- targets connective tissue + gut + inflammation
- TB-500:
- enhances systemic healing + cell movement + blood flow
- Together they:
- hit multiple repair pathways at once
- may improve:
- muscle recovery
- tendon/ligament healing
- inflammation control
Cycle length
- Like the individual peptides:
What’s commonly discussed (non-clinical):
- Typical duration:
- 4–8 weeks
- sometimes 6–12 weeks depending on injury severity
- Often structured as:
- continuous use during that period
- then stop or reassess
Wolverine Blend 20 (10mg BPC 157& 10mg Tb 500) (20 mg/3ml/300units) 15 units = 1mg
- 6–12 units nightly
RECOVERY BLEND
- A treble peptide formulation:
- BPC-157 → gut-derived, tendon/ligament + localized repair
- TB-500 → systemic repair, cell migration, angiogenesis
- KPV → anti-inflammatory peptide
Why they’re combined
- The idea is “synergy”:
- BPC-157:
- targets connective tissue + gut + inflammation
- TB-500:
- enhances systemic healing + cell movement + blood flow
- KPV:
- targets connective tissue + gut + inflammation
- Together they:
- hit multiple repair pathways at once
- may improve:
- muscle recovery
- tendon/ligament healing
- inflammation control
- Gut lining
Cycle length
- Like the individual peptides:
What’s commonly discussed (non-clinical):
- Typical duration:
- 4–8 weeks
- sometimes 6–12 weeks depending on injury severity
- Often structured as:
- continuous use during that period
- then stop or reassess
Recovery Blend 30 (10mg BPC 157& 10mg Tb 500 & KPV 10mg) (300 mg/3ml/300units) 10units = mg
- 6–12 units nightly
GLOW BLEND
- The Glow blend isn’t one official drug—it’s a combo peptide mix, almost always made of:
- GHK-Cu → skin regeneration / collagen
- BPC-157 → tissue repair + anti-inflammatory
- TB-500 → systemic healing + cell migration
- Most commonly:
- ~50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500
What it’s designed for (research context)
- This blend is basically trying to stack three mechanisms at once:
- Skin + cosmetic side (GHK-Cu)
- collagen, elasticity, “glow”
- Localized repair (BPC-157)
- tendons, ligaments, gut
- Systemic repair (TB-500)
- blood flow, cell migration, recovery
- In research, it’s explored for:
- tissue regeneration
- wound healing
- inflammation modulation
- skin biology / anti-aging pathways
Cycle length
- What’s commonly discussed (non-medical / anecdotal):
- 4–8 weeks most typical
- sometimes up to 12 weeks
- From community discussion:
- “cycle 4–5 weeks” (example anecdotal protocol)
- The “cycle” is completely informal, not based on human trials.
Glow 70 (10mg BPC 157, 50mg GHKCU & 10mg TB500) (70 mg/3ml/300units) 4.28 units = 1 mg
- 6–12 units nightly
KLOW BLEND”
- The Klow blend is just a variation of the Glow stack with one extra peptide added:
- GHK-Cu → skin / collagen / regeneration
- BPC-157 → localized tissue repair
- TB-500 → systemic healing
- KPV → anti-inflammatory peptide
What KPV adds
- KPV (Lys-Pro-Val) is a small peptide fragment derived from alpha-MSH
- It’s mainly studied for:
- strong anti-inflammatory effects
- immune modulation
- gut inflammation (IBD-type models)
- skin inflammation (acne, dermatitis models)
- Adding KPV turns Glow into something more inflammation-focused:
- Glow blend:
- regeneration + skin + healing
- Klow blend:
- regeneration + skin + healing + inflammation control
- The theoretical benefit:
- better for:
- irritated skin
- chronic inflammation
- gut + skin crossover issues
Cycle length
- Common anecdotal ranges:
- 4–8 weeks typical
- sometimes up to 10–12 weeks
KLOW 80 (10mg BPC 157, 50mg GHKCU, KPV 10mg & 10mg TB500) (80 mg/3ml/300units)
- 3.75 units = 1mg
- 6–12 units nightly
- Performance & Metabolic Regulation
- MOTS-c
- is a mitochondrial-derived peptide—meaning it’s encoded by mitochondrial DNA rather than nuclear DNA.
- Full name: mitochondrial open reading frame of the 12S rRNA-c
- Discovered relatively recently in metabolic research
- Plays a role in cellular energy regulation
MOTS-c is mainly researched in the context of metabolism and aging.
- Potential effects (mostly animal + early human data):
- Improved insulin sensitivity
- Enhanced glucose metabolism
- Increased fat utilization
- Support for exercise performance
- Possible anti-aging / longevity pathways
- Mechanistically, it’s linked to:
- activation of AMP-activated protein kinase (AMPK)
- regulation of metabolic stress responses
What makes it interesting
- Unlike GLP-1 drugs (semaglutide, tirzepatide):
- Doesn’t suppress appetite directly
- Works more on how your body uses energy
- Think:
- GLP-1s → “eat less”
- MOTS-c → “use energy better”
Cycle length
- 2–4 weeks short protocols
- sometimes 4–8 weeks
- Often used:
- daily or several times per week
- sometimes around training periods
MOTS-C 30 (30 mg/3ml/300units) 10 units = 1mg
- 5-10 units daily or 15-30 units 2x weekly (morning fasted)
SLU-PP-332
- A synthetic experimental compound studied as an ERR (Estrogen-Related Receptor) agonist
- Investigated primarily for effects on:
- metabolic signalling
- mitochondrial activity
- endurance-related pathways
- energy expenditure mechanisms
- Research interest has focused on its potential ability to influence:
- oxidative metabolism
- skeletal muscle energy utilization
- exercise-mimetic signalling pathways
- SLU-PP-332 remains:
- highly experimental
- preclinical in nature
- not an approved therapeutic agent
What it’s studied for
- Research commonly investigates:
- mitochondrial biogenesis pathways
- endurance and exercise signalling
- metabolic flexibility
- fatty acid oxidation mechanisms
- energy expenditure models
- skeletal muscle metabolic activity
Cycle length (research / anecdotal use)
- Common informal / experimental research discussions include
- 4–8 week exploratory protocols
- variable schedules depending on metabolic research objectives
- Often discussed in:
- once-daily research models
- endurance or recomposition-focused protocols
SLU-PP-332 — 10 mg / 3 ml / 300 units
- 5 units = 0.17 mg (170 mcg)
- 10 units = 0.33 mg (330 mcg)
- 15 units = 0.5 mg (500 mcg)
Theoretical research schedule examples
- Low protocol:
- = 5 units daily (≈170 mcg)
- Moderate protocol:
- = 10 units daily (≈330 mcg)
- Higher research example:
- = 15 units daily (≈500 mcg)
10 mg total content example longevity
- 5 units/day → ~60 days
- 10 units/day → ~30 days
- 15 units/day → ~20 days
Common research pairing
- Often discussed alongside:
- mitochondrial-support research compounds
- endurance-focused experimental protocols
- metabolic and recomposition research models
- Due to overlapping energy metabolism signalling interests.
SS-31 (ELAMIPRETIDE)
- A synthetic mitochondria-targeting peptide
- Studied for its interaction with cardiolipin, a phospholipid found in the inner mitochondrial membrane
- Investigated primarily for:
- mitochondrial function support
- cellular energy production pathways
- oxidative stress regulation mechanisms
- SS-31 research focuses heavily on:
- mitochondrial efficiency
- ATP production signalling
- cellular resilience and recovery models
What it’s studied for
- Research commonly investigates:
- mitochondrial bioenergetics
- oxidative stress pathways
- recovery and endurance signalling
- cellular repair mechanisms
- cardiac and skeletal muscle energy models
- neuroprotective and metabolic research applications
Cycle length (research / anecdotal use)
- Common informal / research-style discussions include
- 2–8 week protocols frequently discussed
- sometimes extended in mitochondrial-focused research models
- Often administered:
- once daily
- occasionally split into multiple administrations in experimental settings
SS-31 (Elamipretide) — 30 mg / 3 ml / 300 units
- 5 units = 0.5 mg
- 10 units = 1 mg
- 15 units = 1.5 mg
- 30 units = 3 mg
Theoretical research schedule examples
- Low protocol:
- = 5 units daily (≈0.5 mg)
- Moderate protocol:
- = 10 units daily (≈1 mg)
- Higher research example:
- = 30 units daily (≈3 mg)
30 mg total content example longevity
- 5 units/day → ~60 days
- 10 units/day → ~30 days
- 30 units/day → ~10 days
Common research pairing
- Often discussed alongside:
- mitochondrial-support compounds
- endurance-focused research protocols
- recovery and oxidative stress models
- metabolic and cellular energy pathway research
- Due to overlapping mitochondrial and bioenergetic signalling interests.
CJC-1295 (NO DAC) + IPAMORELIN
- This is a paired peptide protocol used in research contexts to stimulate natural growth hormone (GH) release.
Components:
- CJC-1295 (no DAC)
- A modified version of **growth hormone-releasing hormone
- Signals the pituitary to release GH
- Ipamorelin
- A ghrelin mimetic (growth hormone secretagogue)
- Triggers GH release without strongly increasing cortisol or prolactin
- Together:
- They synergistically increase pulsatile GH release
Why they’re combined
- Each peptide hits a different pathway:
- CJC-1295 → increases baseline GH signaling
- Ipamorelin → triggers GH pulses
- Result:
- more natural GH rhythm vs using either alone
- often described as:
- smoother
- more physiological
Cycle length
- But this combo is one of the more “structured” ones in peptide discussions.
Common informal protocols:
- 8–12 weeks typical
- sometimes extended to:
- 12–16 weeks
- Often followed by:
- a break (e.g. 4 weeks)
CJC-1295 no dac + Ipamorelin 20 (10mg Cjc-1295 & 10mg Ipamorelin) (20 mg/3ml/300units) 15 units = 1mg
- 6–12 units nightly
- Ipamorelin
- is a growth hormone secretagogue—a peptide that stimulates your body to release its own growth hormone (GH).
- It mimics the action of ghrelin
- Acts on the growth hormone secretagogue receptor (GHSR)
- Considered one of the “cleaner” GH-releasing peptides
- Key point:
- It triggers natural GH pulses rather than replacing GH directly
- Ipamorelin is studied for:
- increased growth hormone (GH) and IGF-1
- improved recovery and repair
- better sleep quality
- potential fat loss (indirect)
- mild support for lean mass
Effects are generally
- subtle
- gradual
- dependent on consistency
Cycle length
- Common informal / research-style use:
- 8–12 weeks typical
- sometimes extended to:
- 12–16 weeks
- Often followed by:
- a break period (e.g. a few weeks)
Ipamorelin 20 (20 mg/3ml/300units) 15 units = 1mg
- 6–12 units nightly
CJC-1295 (NO DAC)
- A synthetic GHRH analogue (Growth Hormone Releasing Hormone)
- Designed to stimulate the body’s natural pulsatile release of growth hormone (GH)
- Commonly researched alongside peptides like Ipamorelin
- Unlike DAC versions:
- No DAC = shorter acting
- Typically associated with:
- shorter half-life
- more pulse-like GH release patterns
- more frequent administration in research settings
What it’s studied for
- Research interest commonly includes:
- growth hormone signalling
- IGF-1 modulation
- recovery pathways
- sleep quality mechanisms
- lean tissue preservation
- exercise recovery models
- aging-related endocrine research
Cycle length (research / anecdotal use)
- Common informal / research-style patterns
- 8–12 weeks is frequently discussed
- sometimes extended longer in rotational protocols
- Often administered:
- once nightly
- or split into multiple daily pulses in some research protocols
CJC-1295 (No DAC) — 20 mg / 3 ml / 300 units
- 5 units = 0.33 mg (330 mcg)
- 10 units = 0.67 mg (670 mcg)
- 15 units = 1 mg
Theoretical research schedule examples
- Low protocol:
- = 5 units nightly (≈330 mcg)
- Moderate protocol:
- = 10 units nightly (≈670 mcg)
- Higher research example:
- = 15 units nightly (≈1 mg)
20 mg total content example longevity
- 5 units/day → ~60 days
- 10 units/day → ~30 days
- 15 units/day → ~20 days
Common research pairing
- Often discussed in combination with:
- Ipamorelin
- GHRP-class peptides
- recovery-focused protocols
- Due to complementary GH pulse signalling mechanisms.
TESAMORELIN
- A synthetic Growth Hormone Releasing Hormone (GHRH) analogue
- Designed to stimulate the body’s natural release of growth hormone (GH) and increase IGF-1 levels
- Structurally modified for improved stability and activity compared to native GHRH
- Unlike shorter acting GHRH peptides:
- Tesamorelin generally produces:
- sustained GH signalling
- increased IGF-1 response
- metabolic and body-composition research interest
What it’s studied for
- Research commonly focuses on:
- visceral fat reduction pathways
- growth hormone signalling
- IGF-1 modulation
- metabolic regulation
- recovery mechanisms
- body composition research
- cognitive and neuroprotective pathways
Cycle length (research / anecdotal use)
- Common informal / research-style patterns
- 8–12 weeks frequently discussed
- sometimes extended in longer metabolic research protocols
- Often administered:
- once daily
- commonly in evening or fasted-state research protocols
Tesamorelin — 20 mg / 3 ml / 300 units
- 5 units = 0.33 mg (330 mcg)
- 10 units = 0.67 mg (670 mcg)
- 15 units = 1 mg
Theoretical research schedule examples
- Low protocol:
- = 5 units nightly (≈330 mcg)
- Moderate protocol:
- = 10 units nightly (≈670 mcg)
- Higher research example:
- = 15 units nightly (≈1 mg)
20 mg total content example longevity
- 5 units/day → ~60 days
- 10 units/day → ~30 days
- 15 units/day → ~20 days
Common research pairing
- Often discussed alongside:
- Ipamorelin
- CJC-1295
- metabolic-focused peptide protocols
- recovery and recomposition research models
- Due to complementary GH / IGF-1 pathway interest.
IGF-1 LR3
- A synthetic analogue of Insulin-Like Growth Factor 1 (IGF-1)
- Modified with an extended amino acid chain for:
- longer half-life
- reduced binding to IGF binding proteins
- prolonged biological activity in research settings
- Unlike standard IGF-1:
- LR3 remains active significantly longer
- Often researched for anabolic and recovery-related signalling pathways
What it’s studied for
- Research commonly investigates:
- muscle cell growth signalling
- recovery and regeneration pathways
- nutrient partitioning mechanisms
- insulin sensitivity interactions
- tissue repair models
- performance and hypertrophy research
- cellular growth signalling
Cycle length (research / anecdotal use)
- Common informal / research-style patterns
- 4–6 weeks frequently discussed
- sometimes extended cautiously in longer protocols
- Often administered:
- once daily
- commonly around training-window research protocols
IGF-1 LR3 — 1 mg / 3 ml / 300 units
- 10 units = 33 mcg
Theoretical research schedule examples
- Dosing thoery
- = 10 units After training (≈33 mcg)
1 mg total content example longevity
- 10 units/day → ~30 days
Common research pairing
- Often discussed alongside:
- CJC-1295
- Ipamorelin
- growth hormone secretagogues
- recovery and hypertrophy-focused research protocols
- Due to complementary anabolic signalling pathway interest.
5-AMINO-1MQ
- (5-amino-1-methylquinolinium) is an experimental small molecule, not a peptide, that’s being studied for fat loss and metabolic regulation.
- It works by inhibiting the enzyme nicotinamide N-methyltransferase (NNMT)
- NNMT plays a role in:
- fat storage
- energy metabolism
- cellular methylation balance
- It’s designed to shift the body toward burning fat rather than storing it
Potential effects:
- reduced fat accumulation
- increased metabolic rate
- improved insulin sensitivity
- changes in energy utilization
- It’s often positioned as:
- a “metabolic enhancer”
- not an appetite suppressant (unlike GLP-1 drugs)
- How it’s different from GLP-1 drugs
| Compound | Main mechanism |
|---|---|
| Semaglutide | Appetite suppression |
| Tirzepatide | Appetite + insulin |
| MOTS-c | Cellular energy regulation |
| 5-Amino-1MQ | Fat metabolism via NNMT inhibition |
- GLP-1 → eat less
- 5-Amino-1MQ → burn differently
Cycle length
- 4–8 weeks typical
- sometimes extended to 8–12 weeks
5-Amino-1MQ 50 (50 mg/3ml/300units) 6 units = 1mg
- 10-20 units- morning fasted
- Immunity & Longevity
- Epithalon
- Is (also called Epitalon or Epithalone) is a synthetic peptide derived from a natural peptide called Epithalamin, which comes from the pineal gland.
- Short peptide: 4 amino acids
- Developed in Russia for aging and longevity research
- Often grouped with “anti-aging peptides”
- Potential effects studied:
- activation of telomerase
- possible telomere length support
- improved sleep regulation (via melatonin pathways)
- antioxidant effects
- potential lifespan extension (in animals)
- Big claim:
- It may influence biological aging processes
How it works (simplified)
- Epithalon is thought to:
- act on the pineal gland
- influence melatonin production
- regulate genes linked to aging and cell cycles
Cycle length
- 10–20 days per cycle some extend to 30 days.
- repeated:
- 1–2 times per year
Why people use it
- anti-aging / longevity
- improved sleep quality
- circadian rhythm support
- general “recovery” feeling
Epithalon 50 (50 mg/3ml/300units) 6 units= 1mg
- 10-20 units nightly
Thymosin Alpha-1 is a naturally occurring peptide derived from the thymus gland.
- It’s a fragment of prothymosin alpha
- Plays a role in immune system regulation
- Unlike many peptides you’ve asked about, this one actually has clinical use in some countries
What it’s used for (medical + research)
- TA-1 has been studied and used for:
- immune system support
- chronic viral infections (e.g. hepatitis B/C)
- adjunct therapy in cancer treatment
- immune recovery in weakened states
- It works by:
- enhancing T-cell function
- improving immune signalling and response
How it works (simplified)
- Thymosin Alpha-1 helps:
- activate immune cells (especially T lymphocytes)
- regulate cytokines (immune signalling molecules)
- improve the body’s ability to respond to infections
- FDA approved use in conjunction with chemotherapy for cancer treatment due to t cell boosting properties.
Cycle length
- This one is different because it does have real clinical protocols.
In medical use:
- Often used for:
- several weeks to months
- Example patterns:
- 6–12 weeks common
- sometimes longer depending on condition
Thymosin Alpha-1 20 (20 mg/3ml/300units) 15 units = 1mg
- 30 units 3 x week
PNC-27
- A synthetic experimental peptide studied in oncology-related research
- Designed to interact with HDM-2 (human double minute 2) associated pathways
- Investigated for selective interactions with certain cancer-cell membrane targets in preclinical models
- PNC-27 research remains:
- highly experimental
- primarily preclinical
- not an approved therapeutic agent
What it’s studied for
- Research commonly investigates:
- cancer-cell targeting mechanisms
- membrane pore formation models
- apoptosis and necrosis signalling pathways
- HDM-2 interaction mechanisms
- selective tumor-cell response models
- experimental oncology applications
Cycle length (research / anecdotal use)
- Common informal / experimental research-style discussions include
- 2–6 week exploratory protocols
- variable schedules depending on research design
- Administration frequency in discussions varies widely due to the experimental nature of the compound.
PNC-27 — 10 mg / 3 ml / 300 units
- 5 units = 0.17 mg (170 mcg)
- 10 units = 0.33 mg (330 mcg)
- 15 units = 0.5 mg (500 mcg)
Theoretical research schedule examples
- Low protocol:
- = 5 units daily (≈170 mcg)
- Moderate protocol:
- = 10 units daily (≈330 mcg)
- Higher research example:
- = 15 units daily (≈500 mcg)
10 mg total content example longevity
- 5 units/day → ~60 days
- 10 units/day → ~30 days
- 15 units/day → ~20 days
Common research discussion areas
- Often referenced alongside:
- experimental oncology peptides
- targeted signalling pathway research
- cellular apoptosis and membrane-interaction studies
- Due to its investigational cancer-cell targeting mechanisms.
DSIP (DELTA SLEEP-INDUCING PEPTIDE)
- A naturally occurring neuropeptide originally isolated in sleep-related research
- Studied for potential involvement in:
- sleep regulation
- stress response pathways
- neuroendocrine signalling
- DSIP research is primarily associated with:
- sleep architecture studies
- relaxation and recovery signalling
- circadian and CNS regulatory mechanisms
What it’s studied for
- Research commonly investigates:
- sleep quality pathways
- recovery and relaxation signalling
- stress modulation mechanisms
- circadian rhythm regulation
- neuroendocrine interactions
- fatigue and recovery models
Cycle length (research / anecdotal use)
- Common informal / research-style patterns
- 2–6 weeks frequently discussed
- sometimes used intermittently based on sleep-focused protocols
- Often administered:
- nightly
- typically prior to sleep-focused research periods
DSIP — 10 mg / 3 ml / 300 units
- 5 units = 0.17 mg (170 mcg)
- 10 units = 0.33 mg (330 mcg)
- 15 units = 0.5 mg (500 mcg)
Theoretical research schedule examples
- Low protocol:
- = 5 units nightly (≈170 mcg)
- Moderate protocol:
- = 10 units nightly (≈330 mcg)
- Higher research example:
- = 15 units nightly (≈500 mcg)
10 mg total content example longevity
- 5 units/day → ~60 days
- 10 units/day → ~30 days
- 15 units/day → ~20 days
Common research pairing
- Often discussed alongside:
- CJC-1295
- Ipamorelin
- recovery-focused peptide protocols
- sleep and CNS-support research models
- Due to overlapping recovery and restorative signalling interests.
Hormonal Compounds
Testosterone cypionate is a long-acting ester of testosterone used in testosterone replacement therapy (TRT).
- It’s a form of testosterone
- Designed for slow release after injection
- Commonly prescribed for clinically low testosterone (hypogonadism)
What TRT with testosterone cypionate does
- TRT aims to restore testosterone to a normal physiological range.
- Potential benefits:
- improved energy
- increased libido
- better mood
- improved muscle mass and strength
- increased bone density
Cycle length
- TRT is NOT a cycle
- This is the biggest difference from everything else you’ve asked about.
- ❌ Not 8–12 weeks
- ❌ Not on/off
- ✅ Long-term (often lifelong) therapy
- TRT = continuous hormone replacement, not cycling
- Stopping TRT:
- testosterone levels drop back to baseline (often low again)
- symptoms return
📊 Typical TRT dosing (medical context)
- Usually:
- 100–200 mg per week
- Injection frequency: micro dosed daily or every other day
- TRT typically shuts down natural testosterone production
Fertility note
- TRT can significantly reduce sperm production
- Sometimes managed with:
- human chorionic gonadotropin (hCG)
- TRT vs “cycling steroids”
| TRT | Steroid cycle |
|---|---|
| Medical | Performance use |
| Stable hormone levels | Supraphysiological levels |
| Long-term | Short-term |
| Health-focused | Performance-focused |
- TRT = replacement, not enhancement
TRT Testosterone Cypionate 750(750 mg/3ml/300units) 0.4 units = 1mg
- 6-9 units daily or 12-18 units alternate days
KISSPEPTIN-10
- A synthetic fragment of the naturally occurring kisspeptin peptide family
- Studied for its role in regulating the hypothalamic–pituitary–gonadal (HPG) axis
- Associated with signalling involved in reproductive hormone release
- Kisspeptin research primarily focuses on:
- stimulation of GnRH (Gonadotropin-Releasing Hormone) pathways
- downstream effects on:
- LH (Luteinizing Hormone)
- FSH (Follicle-Stimulating Hormone)
- testosterone and reproductive hormone signalling
What it’s studied for
- Research commonly investigates:
- reproductive endocrine signalling
- testosterone regulation pathways
- fertility and gonadal function models
- HPG-axis modulation
- pituitary hormone signalling
- hypothalamic regulation mechanisms
- Generally acts as a potent tumor suppressor that inhibits metastasis and tumor growth, specific to prostate cancer. Whilst it shows anti cancer effects for prostate cancer this would be the reverse for breast cancer due to the estrogen receptor negative and has shown to be pro towards Glioblastoma.
Cycle length (research / anecdotal use)
- Common informal / research-style patterns
- 2–6 weeks frequently discussed
- often used in shorter endocrine-focused protocols
- Often administered:
- once daily
- or in intermittent pulse-style research schedules
Kisspeptin-10 — 10 mg / 3 ml / 300 units
- 5 units = 0.17 mg (170 mcg)
- 10 units = 0.33 mg (330 mcg)
- 15 units = 0.5 mg (500 mcg)
Theoretical research schedule examples
- Low protocol:
- = 5 units daily (≈170 mcg)
- Moderate protocol:
- = 10 units daily (≈330 mcg)
- Higher research example:
- = 15 units daily (≈500 mcg)
10 mg total content example longevity
- 5 units/day → ~60 days
- 10 units/day → ~30 days
- 15 units/day → ~20 days
Common research pairing
- Often discussed alongside:
- HCG
- enclomiphene
- gonadorelin
- fertility and endocrine-focused peptide protocols
- Due to overlapping reproductive hormone signalling pathways.
PT-141 (BREMELANOTIDE)
- A synthetic melanocortin peptide analogue
- Derived from modifications of Melanotan II research peptides
- Studied primarily for effects related to:
- sexual function signalling
- arousal pathways
- central nervous system melanocortin receptor activity
- Unlike PDE5-focused compounds:
- PT-141 research focuses more on:
- central neurological signalling
- melanocortin receptor activation
- libido and arousal mechanisms
What it’s studied for
- Research commonly investigates:
- sexual arousal pathways
- libido signalling
- melanocortin receptor activity
- CNS-mediated sexual function mechanisms
- erectile function models
- female sexual function research
Cycle length (research / anecdotal use)
- Common informal / research-style patterns
- often used as-needed in research settings
- sometimes studied intermittently over 4–8 week periods
- Typically not discussed as a continuous daily protocol.
PT-141 — 20 mg / 3 ml / 300 units
- 5 units = 0.33 mg (330 mcg)
- 10 units = 0.67 mg (670 mcg)
- 15 units = 1 mg
- 30 units = 2 mg
Theoretical research schedule examples
- Low protocol:
- = 10 units as needed (≈670 mcg)
- Moderate protocol:
- = 15 units as needed (≈1 mg)
- Higher research example:
- = 30 units as needed (≈2 mg)
20 mg total content example longevity
- 10 units/use → ~30 uses
- 15 units/use → ~20 uses
- 30 units/use → ~10 uses
Common research pairing
- Often discussed alongside:
- Melanotan peptides
- libido-focused research compounds
- erectile function pathway research protocols
- Due to overlapping melanocortin signalling mechanisms.
DSIP (DELTA SLEEP-INDUCING PEPTIDE)
- A naturally occurring neuropeptide originally isolated in sleep-related research
- Studied for potential involvement in:
- sleep regulation
- stress response pathways
- neuroendocrine signalling
- DSIP research is primarily associated with:
- sleep architecture studies
- relaxation and recovery signalling
- circadian and CNS regulatory mechanisms
What it’s studied for
- Research commonly investigates:
- sleep quality pathways
- recovery and relaxation signalling
- stress modulation mechanisms
- circadian rhythm regulation
- neuroendocrine interactions
- fatigue and recovery models
Cycle length (research / anecdotal use)
- Common informal / research-style patterns
- 2–6 weeks frequently discussed
- sometimes used intermittently based on sleep-focused protocols
- Often administered:
- nightly
- typically prior to sleep-focused research periods
DSIP — 10 mg / 3 ml / 300 units
- 5 units = 0.17 mg (170 mcg)
- 10 units = 0.33 mg (330 mcg)
- 15 units = 0.5 mg (500 mcg)
Theoretical research schedule examples
- Low protocol:
- = 5 units nightly (≈170 mcg)
- Moderate protocol:
- = 10 units nightly (≈330 mcg)
- Higher research example:
- = 15 units nightly (≈500 mcg)
10 mg total content example longevity
- 5 units/day → ~60 days
- 10 units/day → ~30 days
- 15 units/day → ~20 days
Common research pairing
- Often discussed alongside:
- CJC-1295
- Ipamorelin
- recovery-focused peptide protocols
- sleep and CNS-support research models
- Due to overlapping recovery and restorative signalling interests.
- Get smarter responses, upload files and images, and more.
- NAD⁺
- Is (nicotinamide adenine dinucleotide) is a coenzyme found in every cell of your body and is essential for energy production and cellular health.
- Central to cellular respiration
- Required for:
- converting food into energy (ATP)
- DNA repair
- cell signaling
- NAD⁺ = fuel system regulator for your cells
What it’s studied for
- NAD⁺ has become popular in aging and metabolic research.
- Potential roles:
- improved mitochondrial function
- enhanced energy levels
- support for brain function
- DNA repair and longevity pathways
- possible benefits in addiction recovery (studied clinically in some settings)
- It interacts with:
- sirtuins (linked to aging and metabolism)
Why NAD⁺ declines
- Levels naturally decrease with:
- aging
- stress
- poor metabolic health
- Lower NAD⁺ is associated with:
- fatigue
- reduced metabolic efficiency
- impaired cellular repair
Cycle length
- NAD⁺ isn’t really a “cycle compound” in the traditional sense
Different forms:
- 1. IV / injectable NAD⁺
- Often used in:
- short protocols
- multiple infusions
2. Oral precursors (more common)
- nicotinamide riboside
- nicotinamide mononucleotide
- These are typically:
- taken daily, long-term
- not cycled
Expected effects
- mild increase in energy
- improved recovery feeling
- subtle cognitive benefits
- Important:
effects are usually subtle, not dramatic
- NAD⁺ itself is biologically natural
- Precursors (NR, NMN) are generally well tolerated
- But:
- long-term high-dose effects still being studied
- IV NAD⁺ clinics vary widely in quality
NAD 1000 (1000 mg/3ml/300units) 0.3 units = 1mg
- 5–15 units daily or 10–30 units alternate days
HGH
- Is (Human Growth Hormone) is a naturally occurring hormone produced by the pituitary gland.
- Scientific name: growth hormone
- It regulates:
- growth
- metabolism
- tissue repair
- body composition
- Medical version:
- Somatropin (bioidentical HGH)
What HGH does in the body
- HGH works both directly and through another hormone:
- stimulates liver to produce insulin-like growth factor 1 (IGF-1)
- IGF-1 drives many of the anabolic and recovery effects
Effects:
- increased protein synthesis
- fat metabolism (lipolysis)
- tissue repair and regeneration
- improved bone density
- HGH is prescribed for:
- growth hormone deficiency
- certain genetic conditions
- muscle wasting diseases
- In these cases:
- it’s used as long-term therapy, similar to TRT
Cycle length
- Medically:
- ❌ not cycled
- ✅ continuous, long-term use
Performance / non-medical use:
- People often talk about “cycles,” but:
common informal durations
- 3–6 months minimum
- often 6–12+ months
- Why longer?
- HGH works slowly
- effects take months, not weeks
HGH 100iu (100iu/3ml/300units) 3 units = 1iu
- 9–18 units daily
HCG
- Is (human chorionic gonadotropin) is a hormone that mimics luteinizing hormone (LH) in the body.
- Naturally produced during pregnancy
- In men, it stimulates the testes to produce:
- testosterone
- sperm
- Think of it as:
- a signal to “turn the testes back on”
What hCG is used for
- Medical uses:
- male hypogonadism
- fertility treatment
- delayed puberty
Common non-medical contexts:
- alongside TRT
- post-cycle therapy (PCT)
Why it’s used with TRT
- When someone uses TRT (like testosterone cypionate):
- natural LH production shuts down
- testes stop producing testosterone
- can lead to:
- testicular shrinkage
- reduced fertility
- hCG helps:
- maintain testicular function
- preserve fertility (partially)
- keep some natural testosterone production active
Cycle length (depends on use)
- 1. With TRT (ongoing use)
- Not really cycled
- used continuously alongside TRT
- long-term protocol
2. Post-cycle therapy (PCT)
- Short-term use
- typically 2–4 weeks
- used to restart natural production before
HCG 10000IU (10000iu/3ml/300units) 3 units = 100iu
- 15 units 3 x per week
Cognitive Peptides
- Semax
- is a synthetic peptide nootropic derived from a fragment of adrenocorticotropic hormone (ACTH 4–10).
- Developed in Russia
- Used there clinically (e.g. stroke recovery, cognitive disorders)
- Typically administered as a nasal spray/Sub q Inj
- It’s not a stimulant like caffeine—more of a neuroregulatory peptide
What Semax does
- Semax affects several brain pathways:
- increases brain-derived neurotrophic factor (BDNF)
- modulates dopamine and serotonin
- supports neuroprotection
- In simple terms:
- It helps with focus, memory, and brain resilience
What it’s used for
- Clinical / research use:
- stroke recovery
- cognitive impairment
- neuroprotection
Nootropic use (informal):
- improved focus
- mental clarity
- learning and memory
- reduced brain fog
Cycle length
- No official global standard, but Semax is more structured than most peptides.
Common use patterns:
- 2–4 weeks typical
- sometimes extended to:
- 4–6 weeks
- followed by:
- a break period (e.g. 1–2+ weeks)
- Short cycles with breaks are commonly used
Dosing style
- Usually Sub Q Inj
- Taken:
- Once daily
- Fast-acting:
effects can be noticed within hours to days
- Effects (realistic)
- increased focus and mental energy
- improved memory recall
- smoother cognition (not jittery)
- subtle mood lift
- Compared to stimulants:
- less “wired”
- more stable and clean feeling
Semax 20 (20 mg/3ml/300units) 15 units = 1mg
- 15 units daily
SELANK
- is a synthetic peptide developed in Russia, derived from a fragment of an immune peptide called tuftsin.
- Designed primarily as an anxiolytic (anti-anxiety) peptide
- Typically used as a nasal spray
- Often grouped with nootropic peptides like Semax
- Think of it as:
- a calming, stabilizing brain peptide (not a sedative)
What Selank does
- Selank influences several brain systems:
- modulates gamma-aminobutyric acid (GABA)
- affects serotonin and dopamine balance
- may increase BDNF (neuroplasticity support)
- In simple terms:
- reduces anxiety
- improves emotional stability
- supports cognition indirectly
What it’s used for
- Clinical / research use:
- anxiety disorders
- stress-related conditions
- cognitive support
Nootropic use (informal):
- anxiety reduction without sedation
- improved focus (by lowering mental noise)
- mood stabilization
- social anxiety support
Cycle length
- No universal standard, but commonly structured:
Typical use:
- 2–4 weeks
- sometimes extended to:
- 4–6 weeks
- followed by:
- a break period
- So:
- Short cycles with breaks are standard practice
Dosing style
- Sub Q Inj
- Taken:
- Once daily
Effects
- can be felt within:
- hours to days
- builds gradually with consistent use
Effects (realistic)
- reduced anxiety (without drowsiness)
- calmer mental state
- improved focus (indirectly)
- better stress tolerance
- Compared to medications:
- not as strong as prescription anxiolytics
- but fewer side effects and no sedation
- Selank vs Semax (key difference)
| Peptide | Effect |
|---|---|
| Semax | Stimulating / focus |
| Selank | Calming / anti-anxiety |
- Combined use:
- balances focus + calm
- common in “Know blends”
Selank 20 (20 mg/3ml/300units) 15 units = 1m
- 15 units daily
Melanocortin Peptides
Melanotan II (MT-2)
- is a synthetic peptide analogue of alpha-MSH.
- Designed to stimulate melanin production
- Also affects other receptors in the body (not just skin)
- This is why it has more side effects than Melanotan I
- In simple terms:
- It’s a potent tanning peptide with systemic effects
What it does
- Primary effect:
- increases skin pigmentation (tanning)
Secondary effects (due to broader receptor activity):
- increased libido
- spontaneous erections (in men)
- appetite suppression (mild)
Cycle length
- Common informal structure:
- 1. Loading phase
- ~7–14 days
- frequent dosing
- goal: build baseline pigmentation
- 2. Maintenance phase
- lower frequency dosing
- used to maintain tan
Total duration:
- usually 4–8 weeks
- sometimes longer depending on goals
How fast it works
- initial effects:
- within a few days (flushing, nausea)
- visible tanning:
- 1–3 weeks
- requires:
- some UV exposure for full effect
- It enhances tanning, not replaces sunlight completely
Expected results
- deeper, faster tan
MT-2 20 (20 mg/3ml/300units) 15 units = 1mg
- Days 1–10 = 5 units daily
- 10 units 2-3 times per week
GLUTATHIONE
- A naturally occurring antioxidant composed of:
- glutamine
- cysteine
- glycine
- Found in nearly all cells and heavily involved in:
- oxidative stress regulation
- detoxification pathways
- cellular redox balance
- Research interest commonly focuses on:
- antioxidant defence systems
- liver and cellular detoxification mechanisms
- mitochondrial protection pathways
- recovery and immune-support signalling
What it’s studied for
- Research commonly investigates:
- oxidative stress reduction
- cellular detoxification pathways
- mitochondrial support mechanisms
- immune system signalling
- recovery and fatigue models
- skin and pigmentation pathways
- liver-support research applications
Cycle length (research / anecdotal use)
- Common informal / research-style patterns
- 4–12 week protocols frequently discussed
- sometimes used intermittently or continuously in antioxidant-focused research models
- Often administered:
- daily
- or several times weekly depending on research objective
Glutathione — 1200 mg / 3 ml / 300 units 25 units = 100 mg
Theoretical research schedule examples
- Moderate protocol:
- = 25 units daily (≈100 mg)
- Higher research example:
- = 50 units daily (≈200 mg)
1200 mg total content example longevity
- 25 units/day → ~12 days
- 50 units/day → ~6 days
Common research pairing
- Often discussed alongside:
- NAD+ research compounds
- mitochondrial-support peptides
- recovery and detoxification-focused protocols
- antioxidant and cellular resilience research models
- Due to complementary oxidative stress and cellular protection pathways.
VITAMIN B12 (CYANOCOBALAMIN / METHYLCOBALAMIN)
- A water-soluble essential vitamin involved in:
- red blood cell formation
- neurological function
- DNA synthesis
- energy metabolism
- In research and clinical contexts, B12 is commonly studied for:
- fatigue and energy metabolism
- cognitive and neurological support pathways
- hematologic (blood-related) function
- methylation cycle support
What it’s studied for
- Research commonly investigates:
- energy metabolism and ATP production support
- nerve function and myelin maintenance
- homocysteine metabolism (methylation pathways)
- anemia-related physiology
- cognitive performance and fatigue models
Cycle length (research / general use patterns)
- Common informal / clinical-style patterns
- 4–12 weeks for deficiency correction models
- or ongoing maintenance protocols in supplementation contexts
- Often administered:
- daily
- or several times weekly depending on study design or deficiency severity
Vitamin B12 — 3000 mcg / 3 ml / 300 units 25 units = 250 mcg 50 units = 500 mcg
Theoretical research schedule examples
- Moderate protocol:
- = 25 units daily (≈250 mcg)
- Higher research example:
- = 50 units daily (≈500 mcg)
3000 mcg total content example longevity
- 25 units/day → ~12 days
- 50 units/day → ~6 days
Common research pairing
- Often discussed alongside:
- B-complex vitamins
- NAD+ support protocols
- metabolic and energy-focused supplementation models
- recovery and fatigue-reduction research contexts
- Due to overlapping roles in cellular energy and methylation pathways.